This article was downloaded by: [134.117.10.200] On: 30 December 2014, At: 19:34 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Bioscience, Biotechnology, and Biochemistry Publication details, including instructions for authors and subscription information: <u>http://www.tandfonline.com/loi/tbbb20</u>

## Bacillus subtilis ypgA Gene Is fni, a Nonessential Gene Encoding Type 2 Isopentenyl Diphosphate Isomerase

Motoki TAKAGI<sup>a</sup>, Kazuhide KANEDA<sup>a</sup>, Tomohiro SHIMIZU<sup>a</sup>, Yoichi HAYAKAWA<sup>a</sup>, Haruo SETO<sup>a</sup> & Tomohisa KUZUYAMA<sup>a</sup>

<sup>a</sup> Institute of Molecular and Cellular Biosciences, University of Tokyo Published online: 22 May 2014.

To cite this article: Motoki TAKAGI, Kazuhide KANEDA, Tomohiro SHIMIZU, Yoichi HAYAKAWA, Haruo SETO & Tomohisa KUZUYAMA (2004) Bacillus subtilis ypgA Gene Is fni, a Nonessential Gene Encoding Type 2 Isopentenyl Diphosphate Isomerase, Bioscience, Biotechnology, and Biochemistry, 68:1, 132-137, DOI: <u>10.1271/bbb.68.132</u>

To link to this article: <u>http://dx.doi.org/10.1271/bbb.68.132</u>

### PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <a href="http://www.tandfonline.com/page/terms-and-conditions">http://www.tandfonline.com/page/terms-and-conditions</a>

## *Bacillus subtilis ypgA* Gene Is *fni*, a Nonessential Gene Encoding Type 2 Isopentenyl Diphosphate Isomerase

Motoki Takagi, Kazuhide Kaneda,\* Tomohiro Shimizu, Yoichi Hayakawa, Haruo Seto,\*\* and Tomohisa Kuzuyama<sup>†</sup>

Institute of Molecular and Cellular Biosciences, University of Tokyo, Bunkyo-ku, Tokyo 113-0032, Japan

Received July 18, 2003; Accepted September 5, 2003

We previously identified the fni gene of Streptomyces sp. strain CL190 as type 2 isopentenyl diphosphate (IPP) isomerase, which needs both FMN and NADPH for enzyme activity. An fni gene homolog, ypgA, was detected in the database of the Bacillus subtilis genome. However, the ypgA product was about 140 amino acids shorter in the N-terminal than the Streptomyces fni gene product. A database search found three new putative start codons in 129, 225, and 411 bases upstream of the original start codon of the ypgA gene. The longest gene product, which was named *vpgA3*, showed the most significant homology to the Streptomyces fni gene product. The ypgA3 gene was expressed with an Nterminal His-tag in Escherichia coli and the purified soluble protein was characterized in detail. The ypgA3 protein converted IPP to its isomer dimethylallyl diphosphate in the presence of both FMN and NADPH. The enzyme also catalyzed the reverse reaction in the presence of both the cofactors. Disruption of the ypgA3 gene was not lethal to B. subtilis. These results indicate that Bacillus ypgA3 gene is fni, a nonessential gene encoding type 2 IPP isomerase.

### Key words: isoprenoid; biosynthesis; *Bacillus subtilis*; isomerase; 2-*C*-methyl-D-erythritol 4-phosphate (MEP) pathway

All terpenoids are synthesized by consecutive condensations of a five-carbon-basic unit, isopentenyl diphosphate (IPP) to its isomer, dimethylallyl diphosphate (DMAPP).<sup>1)</sup> IPP isomerase (EC 5.3.3.2) catalyzes an important reaction in the biosynthesis of terpenoids by converting IPP to DMAPP (Fig. 1).<sup>2)</sup> Many IPP isomerase genes, which are encoded by *idi* genes, have been cloned from various organisms such as humans,<sup>3)</sup> *Saccharomyces cerevisiae*,<sup>4)</sup> *Escherichia coli*,<sup>5)</sup> and *Rhodobacter capsulatus*.<sup>6)</sup> This enzyme needs only a divalent cation such as Mg<sup>2+</sup> for its enzyme activity. However, we previously identified an open reading frame of *Streptomyces* sp. strain CL190 as a new type of IPP isomerase that strictly needs both FMN and NADPH for enzyme activity.<sup>7)</sup> The amino acid sequence of this new IPP isomerase, designated as type 2 IPP isomerase, shares no similarity to those of the *idi* gene products. The *fni* gene homologs encoding type 2 IPP isomerase are found in the gene cluster of the mevalonate pathway not only from *Streptomyces* sp. strain CL190, but also from *Borrelia burgdorferi*, and Gram-positive cocci such as *Staphylococcus aureus* and *Enterococcus faecalis*. This fact implied that the *fni* gene is specific for the mevalonate pathway.

Two distinct biosynthetic pathways for IPP and DMAPP are known (Fig. 1).<sup>8–12)</sup> One is the well-known mevalonate pathway (Fig. 1A), which operates in eukaryotes, archaebacteria, Gram-positive cocci, and cytosols of higher plants. The other is a recently discovered pathway, the 2-*C*-methyl-D-erythritol 4-phosphate (MEP) pathway (formerly called the non-mevalonate pathway) (Fig. 1B), which is used by most eubacteria, green algae, and the chloroplasts of higher plants. In *E. coli* with the MEP pathway, IPP isomerase is not essential, because IPP and DMAPP are biosynthesized independently (Fig. 1B).

*Bacillus subtilis* has all the genes of the MEP pathway and therefore uses this pathway for the biosynthesis of IPP and DMAPP.<sup>13)</sup> In addition to these genes, an *fni* gene homolog, *ypgA*, was detected in the database of the *B. subtilis* genome.<sup>14)</sup> However, it was ambiguous that the *ypgA* gene product actually had IPP isomerase activity, because the amino acid sequence of the gene product was about 140 amino acids shorter in the Nterminal than the *fni* gene products from *Streptomyces* sp. strain CL190 and *S. aureus*.

In these studies, we found an actual start codon for the *ypgA* gene. In this paper, we describe the first unambiguous assignment of the *ypgA* gene product as type 2 IPP isomerase and the enzymatic properties of the *ypgA* gene products overexpressed in *E. coli*.

\*\* Present address: Department of Applied Biology and Chemistry, Tokyo University of Agriculture, Setagaya-ku, Tokyo 156-8502, Japan

<sup>&</sup>lt;sup>†</sup> To whom correspondence should be addressed. Fax: +81-3-5841-8485; E-mail: kuz@iam.u-tokyo.ac.jp

<sup>\*</sup> Present address: Shizuoka Eiwa Gakuin University Junior College, 1769 Ikeda, Shizuoka, Shizuoka 422-8005, Japan

Abbreviations: IPP, isopentenyl diphosphate; DMAPP, dimethylallyl diphosphate; MEP, 2-C-methyl-D-erythritol 4-phosphate

#### A: mevalonate pathway



Fig. 1. Mevalonate and MEP Pathways for IPP and DMAPP Biosyntheses.

In the MEP pathway, both IPP and DMAPP are formed from HMBDP by the action of the *lytB* gene product. HMG-CoA, 3-hydroxy-3-methylglutaryl-CoA; DPMVA, diphosphomevalonate; IPP, isopentenyl diphosphate; DMAPP, dimethylallyl diphosphate; DXP, 1-deoxy-D-xylulose 5-phosphate; MEP, 2-*C*-methyl-D-erythritol 4-phosphate; MECDP, 2-*C*-methyl-D-erythritol 2,4-diphosphate; HMBDP, *E*-4-hydroxy-3-methyl-2-butenyl diphosphate.

### **Materials and Methods**

*Strains and vectors. B. subtilis* 168 strain (wild-type) and the *ypgA* gene-disruptant were kindly provided by Prof. Ogasawara of the Nara Institute of Science and Technology. This disruptant has the erythromycin-resistance gene in the *ypgA* gene. pQE30, an expression vector in *E. coli*, was purchased from Qiagen.

Growth conditions for B. subtilis. Fresh B. subtilis cells were suspended in LB medium and the optical density at 655 nm of this cell suspension was adjusted to  $10^{-3}$ . One hundred  $\mu$ l of the cell suspension was incubated in a well of a 96-well microplate at 37°C with shaking (700 rpm/min). The growth of the cell was monitored at 655 nm with a Benchmark Microplate Reader (BIORAD) adjusted at 37°C.

*DNA sequence analysis.* The DNA sequence was analyzed by the dideoxynucleotide chain-termination method<sup>15)</sup> with an automated sequencer (model 4000L, Li-cor) and the protocol of the supplier. The FASTA program<sup>16)</sup> did homology searches with protein databases of the DNA Data Bank of Japan (DDBJ) and the National Center for Biotechnology Information (NCBI). A GENETYX program ver. 11 (Software Development, Tokyo, Japan) was used to search for putative start codons and to align amino acid sequences.

Construction of the Plasmid for Overexpression of ypgA3 in E. coli. On the basis of the nucleotide sequence of ypgA3 from B. subtilis 168, two oligonucleotide primers, 5'-GGGGATCC ACTCGAGCAGAACGAAA-AAGAC-3' (5' of ypgA3) and 5'-GGGGATCC TCGCA-

CACTATAGCTTGATGTATTG-3' (3' of *ypgA3*), including a *Bam*HI restriction site (underlined) were synthesized (Sigma) and used together with total DNA from *B. subtilis* 168 to amplify *ypgA3*. By using Taq DNA polymerase (Roche Molecular Biochemicals) and the protocol recommended by the supplier, a 1.1-kb fragment was amplified. The PCR fragment was digested with *Bam*HI and cloned into the multi-cloning site of the expression vector pQE30 to give pQEYpgA3.

Expression and Purification of the Recombinant ypgA3 Product. E. coli M15 containing pREP4 [neo, *lacI* (Qiagen) was used as a host for the expression of ypgA3. M15 (pREP4, pQEYpgA3) was cultured at 18°C in one liter of LB medium containing  $25 \,\mu g/ml$ kanamycin (Nacalai Tesque, Kyoto) and  $200 \,\mu g/ml$ ampicillin (Sigma) for 6h with the addition of 0.1 mM isopropyl- $\beta$ -D-thiogalactopyranoside (IPTG) when an optical density at 660 nm of 0.8 was reached. Cells were harvested by centrifugation and resuspended in Buffer A, composed of 100 ml of 0.1 M Tris-HCl (pH 8.0) and 5 mM DTT. After sonication, the lysate was centrifuged at  $10,000 \times g$  for 20 min and the supernatant was retained. The crude extract was put on a Ninitrilotriacetic acid agarose column (Qiagen) previously equilibrated with Buffer A. The resin was washed with 50 mM imidazole in Buffer A and then the protein bound to the resin was eluted with 200 mM imidazole in Buffer A.

Assay for type 2 IPP isomerase. An assay system for type 2 IPP isomerase was based on the acid lability of DMAPP. This assay mixture consisted of 0.1 M HEPES buffer (pH 7.0), 5 mM MgCl<sub>2</sub>, 1 mM DTT,  $10 \,\mu$ M  $[1^{-14}C]$ IPP (2.0 GBq/mmol; American Radiolabeled Chemicals, USA), 40  $\mu$ M IPP, 10  $\mu$ M FMN and 1 mM NADPH in a final volume of 50  $\mu$ l. The reaction was started by adding enzyme to the assay system followed by incubation routinely at 37°C for 1 min. Further manipulations were done as described before.<sup>7)</sup>

pH-Dependent Activity of IPP isomerase. The IPP isomerase assay was done as described above. Assay solutions consisted of 0.1 M MES at pH 5.0–6.5, 0.1 M HEPES at pH 6.5–7.5 or 0.1 M Tris-HCl at pH 7.0–9.5, 5 mM MgCl<sub>2</sub>, 10  $\mu$ M FMN, 5 mM NADPH and 1 mM DTT.

Nucleotide sequence accession number. The nucleotide sequence of the *fni* gene of *B. subtilis* has been deposited in the DDBJ/EMBL/GenBank nucleotide sequence databases with the accession number AB047343.

### Results

# Identification of the fni gene homolog in the B. subtilis genome

To identify fni gene homologs in the B. subtilis genome, homology searches that use the sequence of the fni gene product from Streptomyces sp. strain CL190 as a query sequence was done using databases of DDBJ and NCBI. This search identified a ypgA gene product (accession no. L47648) with unknown function.<sup>14)</sup> Figure 2 shows the multiple alignment of the amino acid sequences of the ypgA gene product and the FNI homologs from Streptomyces and Staphylococcus. The Bacillus gene product showed significant homology to these FNI homologs. However, the ypgA product was about 140 amino acids shorter in the N-terminal than the FNI homologs. This finding led us to assume that there is another start codon upstream of the original one. As expected, a database search found three new putative start codons in 129, 225, and 411 nucleotides upstream of the original start codon of the ypgA gene (Fig. 2). The corresponding genes were named ypgA1, ypgA2, and ypgA3, respectively. The longest gene product, YPGA3, showed most significant homology to the Streptomyces fni gene product, suggesting that the ypgA3 gene actually encodes Bacillus FNI (Fig. 2). The stop codon for ypfD gene flanking the ypgA gene was found 15 nucleotides upstream of the start codon for the ypgA3, also supporting the above suggestion.

### *Expression and Purification of the recombinant ypgA3 product*

To discover the *in vitro* function of the ypgA3 product, the ypgA3 was expressed with an N-terminal His-tag in *E. coli* using the T7 promoter system and the product was purified to homogeneity as a soluble protein. After purification, the concentrated protein solution was yellow, as was the *fni* protein from

Streptomyces sp. strain CL190, indicating that the ypgA3 product is also a flavoprotein. SDS-PAGE showed a subunit molecular mass of 41 kDa. The apparent molecular mass of the ypgA3 product was estimated to be 135 kDa by Superdex 200 gel filtration. These data indicate that the ypgA3 product is most likely to be a tetramer. When we attempted to overexpress the ypgA, ypgA1, and ypgA2 genes in *E. coli* by the same method as that for the ypgA3 gene, we were able to obtain insoluble proteins but not soluble proteins.

### FMN/NADPH-dependent IPP isomerase activity of the recombinant ypgA3 product

We next investigated whether the recombinant ypgA3 product catalyzes conversion of IPP and DMAPP in the presence of FMN and NADPH. As expected, the ypgA3 product showed IPP isomerase activity in the presence of both the cofactors, confirming that the gene actually encodes type 2 IPP isomerase (Table 1). The activity was maximal when  $10 \,\mu\text{M}$  FMN and  $1 \,\text{mM}$  NADPH were added. The activity was slightly below maximal when 10 µM FMN and 1 mM NADH was used. However, replacement of FMN with FAD resulted in the loss of IPP isomerase activity. Without addition of FMN or NADPH, no activity was detected, demonstrating that IPP isomerization catalyzed by the ypgA3 product was strictly dependent on both FMN and NADPH. This enzyme required Mg<sup>2+</sup>, Mn<sup>2+</sup>, or Ca<sup>2+</sup>. The activity was maximal with Mg<sup>2+</sup>, but lower with Mn<sup>2+</sup> and  $Ca^{2+}$ . No effects of other divalent cations such as  $Co^{2+}$ ,  $Cu^{2+}$ , and  $Zn^{2+}$  at 5 mM were detected. Addition of 5 mM EDTA resulted in almost complete loss of the enzyme activity.

The IPP isomerase encoded by *ypgA3* was most active in HEPES buffer. The optimum activity of the enzyme occurred at pH 6.5–7.0. The effects of temperature on the enzyme activity were investigated over the range of 15 to 55°C, with the maximum activity being observed at approximately 37°C. Table 2 summarizes enzymatic properties of type 2 IPP isomerases from *B. subtilis*, *Streptomyces* sp. strain CL190,<sup>7)</sup> and *S. aureus*.<sup>7)</sup>

### Phenotype of the Bacillus-ypgA3-disruptant

To investigate *in vivo* function of the *ypgA3* gene, a *Bacillus-ypgA3*-disruptant was cultivated in liquid LB medium. The growth curve revealed that the disruption of the gene had no apparent effects on growth. Fosmidomycin  $(3.1 \,\mu g/ml)$ , a specific inhibitor of DXP reductoisomerase of the MEP pathway,<sup>17)</sup> completely inhibited the growths of both *B. subtilis* 168 and the *ypgA3*-disruptant, showing that enough IPP and DMAPP to support growth were not supplied from LB medium. These results demonstrate that *ypgA3* is a nonessential gene for *B. subtilis* growth.

### Discussion

In this study, we have demonstrated that the B.

Bsub CL190 Saur HAO	1 1 1 1		IT FDDV FDKM VSKI
Bsub CL190 Saur HAO	30 31 32 59	► YPGA2 -FVHVSLPDL-ALEQVDISTKIGELSSSSPIFINAMTGGGGKLTYEINKSLARAAS SFVHHALAGI-DRPDVSLATSFAGISWQVPIYINAMTGGSEKTGL-INRDLATAAR RFVHHSIPSI-NVNDIDLTSQTPDLTMAYPVYINAMTGGSEWTKN-INEKLAVVAR DMTTTVLGFKISMPIMVAPTAMQKMAHPDGEYATARAASAAGTIMTLSSWATSSVE	QAGI ETGV ETGL EVAS
Bsub CL190 Saur HAO	88 89 90 119	YPGA1 PLAVGSQMSALKDPSERLSYEI-VRKENPNGLIFANLGSEATAAQAKEAVEMI-GA PIASGSMNAYIKDPSCADTFRV-LRDENPNGFVIANINATTTVDNAQRAIDLI-EA AMAVGSTHAALRNPRMAETFTI-ARKMNPEGMIFSNVGADVPVEKALEAVELL-EA TGP-GIRFFQLYVYKNRNVVEQLVRRAERAGFKAIALTVDTPRLGRRESDIKNRFT	YGA NALQ QALQ LPPN
Bsub CL190 Saur HAO	146 147 148 178	* IHLNVIQEIVMPEGDRSFSGALKRIEQICSRVSVPVIVKEVGFGMSKASAGKLYEA IHINTAQETPMPEGDRSFASWVPQIEKIAAAVDIPVIVKEVGNGLSRQTILLLADL IHVNSPQELVMPEGNREFVTWLDNIASIVSRVSVPVIIKEVGFGMSKELMHDLQQI LTLKNFEGLDLGKMDEANDSGLASYVAGQIDRTLSWKDVQWLQTITKLPILVKG	GAAA GVQA GVKY VLTG
Bsub CL190 Saur HAO	206 207 208 236	VDIG <mark>GYGGTNF</mark> SK-IENLRRQRQISFFNS-WGISTAASLAEIRSEFPASTMIASGG ADVSGRGGTDFAR-IENGRRELGDYAFLHGWGQSTAACLLDAQDISLPVLASGG VDVSGKGGTNFVD-IENERRANKDMDYLSSWGQSTVESLLETTAYQSEISVFASGG ED RIAIQAGAAGIIVSNHGARQLDYVPATISALEEVVKATQGRIPVFLDGG #	LQDA VRHP LRTP VRRG
Bsub CL190 Saur HAO	264 264 267 292	LDVAKA <mark>I</mark> ALGASCTGMAG-HFLKALTDSGEEGLLEEIQLILEELKLIMTVLGARTI LDVVRALALGARAVGSSA-GFLRTLMDDGVDALITKLTTWLDQLAALQTMLGARTP LDAIKSLALGAKATGMSR-PFLNQVENNGIAHTVAYVESFIEHMKSIMTMLDAKNI TDVFKALALGASGIFI-GRPVVFSLAAEGEAGVRKVLQMLRDEFELTMALSGCRSL	ADLQ ADLT DDLT KEIS
Bsub CL190 Saur HAO	323 323 326 351	KAPLVIKG <mark>ETHHWLTER</mark> GVNTSSYSVR349 RCDVLLHGELRDFCADRGIDTRRLAQRSSSIEALQTTGSTR 363 QKQIVFSPEILSWIEQRNLNIHRG349 RNHITTEWDTPRPSARL367	

Fig. 2. Amino Acid Alignment of Type 2 IPP Isomerases and (S)-2-Hydroxy-acid Oxidase.

The putative first methionines of YPGA are marked by arrows. The type 2 IPP isomerases from three origins were aligned with (*S*)-2-hydroxyacid oxidase from *A. thaliana* using the GENETYX program. Amino acid residues conserved among 3 or 4 proteins are boxed. Dashes indicate gaps introduced for the optimization of the alignment. The highly conserved His residues are marked by an asterisk and the His254 in the active site of (*S*)-2-hydroxy-acid oxidase is marked by a sharp. Bsub, *B. subtilis* (accession no. AB047343); CL190, *Streptomyces* sp. strain CL190 (accession no. AB046667); Saur, *S aureus* (accession no. AB047344); HAO, *A. thaliana* (*S*)-2-hydroxy-acid oxidase (accession no. Q9LRR9).

subtilis ypgA3 gene is a nonessential gene encoding type 2 IPP isomerase and compared the kinetic parameters of the *B. subtilis* enzyme to those of *Streptomyces* and *Staphylococcus* homologs. *B. subtilis* enzyme was also a flavoprotein and had FMN- and NAD(P)H-dependent IPP isomerase activity. The enzymatic properties of the *B. subtilis* enzyme were almost the same as those of the *Streptomyces* enzyme (Table 2). However, the  $K_m$  value for IPP of the *B. subtilis* enzyme was about 30-fold higher than that of the *S. aureus* enzyme. This higher value might be explained by the non-essentiality of type 2 IPP isomerase for *B. subtilis* growth. On the other hand, type 2 IPP isomerase is essential for the growth of *S. aureus*. Therefore, the  $K_m$  value of type 2 IPP

isomerase of *S. aureus* could be lower than those of IPP isomerase from *Streptomyces* sp. strain CL190 and *B. subtilis*, both of which use the MEP pathway for growth.

It should be noted that two types of IPP isomerases are widespread in microorganisms.<sup>12)</sup> To the best of our knowledge, all archaebacteria, which use the mevalonate pathway, have type 2 IPP isomerase. In eubacteria, Gram-positive cocci such as *Staphylococcus*, *Streptococcus*, and *Enterococcus*, which also use the mevalonate pathway, have type 2 enzyme. *E. coli* with the MEP pathway has type 1 IPP isomerase, as do all eukaryotes. Interestingly, *B. subtilis* and *Synechocystis* sp. strain PCC6803 using the MEP pathway have type 2 IPP isomerases, which are nonessential for their growth.

 Table 1. FMN and NAD(P)H Dependence of the Activity of the Bacillus IPP Isomerase

Additions to rea		
FMN or FAD, $\mu$ M	NAD(P)H, mM	relative activity, %
FMN	NADPH	
0	0	ND
0	1	2.7
10	0	4.1
10	1	100
10	1	97.8
FAD	NADPH	
10	1	ND

<sup>a</sup> The basal reaction buffer consisted of 0.1 M HEPES (pH 7.0), 5.0 mM MgCl<sub>2</sub>, 1 mM DTT, 5  $\mu$ g enzyme. ND, not detected.

 Table 2.
 Comparison of Enzymatic Properties of Type 2 IPP

 Isomerases
 Isomerases

	B. subtilis	CL190*	S. aureus*
$K_m$ for IPP ( $\mu$ M)	670	450	19
$V_{max}$ (mmol/min/mg of protein)	400	490	270
Optimum temperature (°C)	37	35	NA
Optimum pH	6.5-7.0	7.0	NA
Divalent cations	$Mg^{2+}$	$Mg^{2+}$	$Mg^{2+}$
Molecular mass			
SDS-PAGE (kDa)	40	42	41
Superdex-200 (kDa)	135	135	155
Multimeric form	tetramer	tetramer	tetramer

\*These data were cited from reference number 7. NA, not available.

Expression analysis with DNA microarray of *B. subtilis* has revealed that the *ypgA* gene is actually expressed in the exponential growth period (Kobayashi, K., personal communication), demonstrating that *B. subtilis* uses the *ypgA* gene to supply DMAPP from IPP. On the other hand, it has been demonstrated that *Synechocystis* IPP isomerase had no function *in vivo*.<sup>18,19</sup> Therefore, *B. subtilis* represents the first example of a microorganism that uses both the MEP pathway and type 2 IPP isomerase for the biosynthesis of the isoprene units, IPP and DMAPP.

It is also very interesting that two types of the enzymes showing no sequence homology catalyze the same reaction. How does nature evolve these two types of IPP isomerases? What are the roles of FMN and NADPH in the reaction catalyzed by type 2 IPP isomerase? These are the next questions to be answered.

In order to gain insight into these questions, homology searches that use the sequence of *Streptomyces* FNI as a query were done using the FASTA program and the SWISS-PROT database. Interestingly, this search identified (*S*)-2-hydroxy-acid oxidase (accession no. Q9LRR9) from *Arabidopsis thaliana* (22.1% identity in 339 amino acids overlap).<sup>20)</sup> This enzyme is a flavoprotein and belongs to the FMN-dependent  $\alpha$ hydroxy acid dehydrogenases family. Multiple amino acid alignment (Fig. 2) identified two conserved regions, <sup>258</sup>GG(L/V)(R/Q) and <sup>265</sup>D(V/A)X(K/R)(A/S)(I/L)-ALGA in the *B. subtilis* FNI. These conserved regions could in part associate with FMN binding in the enzyme molecule, because both the enzymes strictly need FMN as the common cofactor. In addition, His254 in (*S*)-2hydroxy-acid oxidase has been proposed to remove the  $\alpha$ -proton of the substrate as the first step in catalysis (Fig. 2).<sup>21)</sup> In analogy with this enzyme, the highly conserved His147 in *B. subtilis* IPP isomerase might be involved in the removal of 2-H of the IPP molecule (Fig. 2).

During preparation of this paper, Steinbacher *et al.* reported the crystal structure of type 2 IPP isomerase from *B. subtilis*.<sup>22)</sup> The structural analysis revealed that the phosphate function of FMN was hydrogen bonded to the amide of Gly259 of the glycine-rich motif <sup>258</sup>GG-(L/V)(R/Q) mentioned above and to the amides of Ala280 and Gly28. Also, His147 in the crystal structure is located near the FMN molecule, suggesting that this residue could play an important role in catalysis, as discussed above. This crystal structure will help to clarify the mechanism of the unusual isomerase reaction.

### Acknowledgments

We sincerely thank Dr. K. Kobayashi, Graduate School of Information Science, Nara Institute of Science and Technology, and Dr. Hiromi Nishida, Institute of Molecular and Cellular Biosciences, The University of Tokyo, for fruitful discussions. This work was supported by a Grant-in-Aid for Scientific Research on Priority Areas, "Genome Biology", to T.K. from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

### References

- Cane, D. E., Isoprenoid biosynthesis overview. In "Comprehensive Natural Products Chemistry", eds. Barton, D. H. R., and Nakanishi, K., Elsevier, Oxford, pp. 1–484 (1999).
- Ramos-Valdivia, A. C., van der Heijden, R., and Verpoorte, R., Isopentenyl diphosphate isomerase: a core enzyme in isoprenoid biosynthesis. A review of its biochemistry and function. *Nat. Prod. Rep.*, 14, 591–603 (1997).
- Hahn, F. M., Xuan, J. W., Chambers, A. F., and Poulter, C. D., Human isopentenyl diphosphate:dimethylallyl diphosphate isomerase: overproduction, purification, and characterization. *Arch. Biochem. Biophys.*, 332, 30–34 (1996).
- Anderson, M. S., Muehlbacher, M., Street, I. P., Proffitt, J., and Poulter, C. D., Isopentenyl diphosphate:dimethylallyl diphosphate isomerase. An improved purification of the enzyme and isolation of the gene from *Saccharomyces cerevisiae*. J. Biol. Chem., 264, 19169–19175 (1989).
- 5) Hahn, F. M., Hurlburt, A. P., and Poulter, C. D., *Escherichia coli* open reading frame 696 is *idi*, a

nonessential gene encoding isopentenyl diphosphate isomerase. *J. Bacteriol.*, **181**, 4499–4504 (1999).

- Hahn, F. M., Baker, J. A., and Poulter, C. D., Open reading frame 176 in the photosynthesis gene cluster of *Rhodobacter capsulatus* encodes *idi*, a gene for isopentenyl diphosphate isomerase. *J. Bacteriol.*, **178**, 619– 624 (1996).
- Kaneda, K., Kuzuyama, T., Takagi, M., Hayakawa, Y., and Seto, H., An unusual isopentenyl diphosphate isomerase found in the mevalonate pathway gene cluster from *Streptomyces* sp. strain CL190. *Proc. Natl. Acad. Sci. USA*, **98**, 932–937 (2001).
- Rohmer, M., The discovery of a mevalonate-independent pathway for isoprenoid biosynthesis in bacteria, algae and higher plants. *Nat. Prod. Rep.*, 16, 565–574 (1999).
- Rohdich, F., Kis, K., Bacher, A., and Eisenreich, W., The nonmevalonate pathway of isoprenoids: genes, enzymes and intermediates. *Curr. Opin. Chem. Biol.*, 5, 535–540 (2001).
- Eisenreich, W., Rohdich, F., and Bacher, A., Deoxyxylulose phosphate pathway to terpenoids. *Trends Plant Sci.*, 6, 78–84 (2001).
- Kuzuyama, T., Mevalonate and nonmevalonate pathways for the biosynthesis of isoprene units. *Biosci. Biotechnol. Biochem.*, 66, 1619–1627 (2002).
- Kuzuyama, T., and Seto, H., Diversity of the biosynthesis of the isoprene units. *Nat. Prod. Rep.*, 20, 171–183 (2003).
- 13) Kobayashi, K., Ehrlich, S. D., Albertini, A., Amati, G., Andersen, K. K., Arnaud, M., Asai, K., Ashikaga, S., Aymerich, S., Bessieres, P., Boland, F., Brignell, S. C., Bron, S., Bunai, K., Chapuis, J., Christiansen, L. C., Danchin, A., Debarbouille, M., Dervyn, E., Deuerling, E., Devine, K., Devine, S. K., Dreesen, O., Errington, J., Fillinger, S., Foster, S. J., Fujita, Y., Galizzi, A., Gardan, R., Eschevins, C., Fukushima, T., Haga, K., Harwood, C. R., Hecker, M., Hosoya, D., Hullo, M. F., Kakeshita, H., Karamata, D., Kasahara, Y., Kawamura, F., Koga, K., Koski, P., Kuwana, R., Imamura, D., Ishimaru, M., Ishikawa, S., Ishio, I., Le, Coq D., Masson, A., Mauel, C., Meima, R., Mellado, R. P., Moir, A., Moriya, S., Nagakawa, E., Nanamiya, H., Nakai, S., Nygaard, P., Ogura, M., Ohanan, T., O'Reilly, M., O'Rourke, M., Pragai, Z., Pooley, H. M., Rapoport, G., Rawlins, J. P., Rivas, L. A., Rivolta, C., Sadaie, A., Sadaie, Y., Sarvas, M., Sato, T., Saxild, H. H., Scanlan, E., Schumann, W., Seegers, J. F., Sekiguchi, J., Sekowska, A., Seror, S. J.,

Simon, M., Stragier, P., Studer, R., Takamatsu, H., Tanaka, T., Takeuchi, M., Thomaides, H. B., Vagner, V., van Dijl, J. M., Watabe, K., Wipat, A., Yamamoto, H., Yamamoto, M., Yamamoto, Y., Yamane, K., Yata, K., Yoshida, K., Yoshikawa, H., Zuber, U., and Ogasawara, N., Essential *Bacillus subtilis* genes. *Proc. Natl. Acad. Sci. USA*, **100**, 4678–4683 (2003).

- Sorokin, A., Zumstein, E., Azevedo, V., Ehrlich, S. D., and Serror, P., The organization of the *Bacillus subtilis* 168 chromosome region between the *spoVA* and *serA* genetic loci, based on sequence data. *Mol. Microbiol.*, 10, 385–395 (1993).
- Sanger, F., Nicklen, S., and Coulson, A. R., DNA sequencing with chain-terminating inhibitors. *Proc. Natl. Acad. Sci. USA*, 74, 5463–5467 (1977).
- 16) Pearson, W. R., and Lipman, D. J., Improved tools for biological sequence comparison. *Proc. Natl. Acad. Sci.* USA, 85, 2444–2448 (1988).
- Kuzuyama, T., Shimizu, T., Takahashi, S., and Seto, H., Fosmidomycin, a specific inhibitor of 1-deoxy-D-xylulose 5-phosphate reductoisomerase in the nonmevalonate pathway for terpenoid biosynthesis. *Tetrahedron Lett.*, 39, 7913–7916 (1998).
- Ershov, Y., Gantt, R. R., Cunningham, F. X., and Gantt, E., Isopentenyl diphosphate isomerase deficiency in *Synechocystis* sp. strain PCC6803. *FEBS Lett.*, **473**, 337–340 (2000).
- 19) Ershov, Y. V., Gantt, R. R., Cunningham, F. X., and Gantt, E., Isoprenoid biosynthesis in *Synechocystis* sp. strain PCC6803 is stimulated by compounds of the pentose phosphate cycle but not by pyruvate or deoxyxylulose-5-phosphate. *J. Bacteriol.*, **184**, 5045–5051 (2002).
- 20) Sato, S., Nakamura, Y., Kaneko, T., Katoh, T., Asamizu, E., and Tabata, S., Structural analysis of *Arabidopsis thaliana* chromosome 3. I. Sequence features of the regions of 4,504,864 bp covered by sixty P1 and TAC clones. *DNA Res.*, 7, 131–135 (2000).
- Lindqvist, Y., and Branden, C. I., The active site of spinach glycolate oxidase. J. Biol. Chem., 264, 3624– 3628 (1989).
- 22) Steinbacher, S., Kaiser, J., Gerhardt, S., Eisenreich, W., Huber, R., Bacher, A., and Rohdich, F., Crystal structure of the type II isopentenyl diphosphate:dimethylallyl diphosphate isomerase from *Bacillus subtilis*. J. Mol. Biol., **329**, 973–982 (2003).